Investigational eIF2B activator DNL343 modulates the integrated stress response in preclinical models of TDP-43 pathology and individuals with ALS in a randomized clinical trial

Brittany N. Flores(Denali Therapeutics (United States)), Joseph W. Lewcock(Denali Therapeutics (United States))
Nature Communications
August 18, 2025
Cited by 5


Related Papers